BOCA RATON,
Fla., Jan. 17, 2012
/PRNewswire/ -- Vycor Medical, Inc. (OTCBB: VYCO) ("Vycor")
today announced that its ViewSite Brain Access System ("VBAS") has
received clearance from the State Food and Drug Administration
("SFDA") in the People's Republic of
China ("PRC") to be imported and marketed in the PRC. This
follows the issue of its patent in China for VBAS in 2011.
Kenneth
Coviello, the Chief Executive of Vycor, commented: "We are
delighted to have achieved this important milestone in Vycor's
development. VBAS has received outstanding reviews from surgeons in
the United States where it
continues to gain traction with hospitals and neurosurgeons. We
believe that the Chinese medical device market has tremendous
potential for Vycor and are excited to begin working with
healthcare professionals in China
and look forward to the expansion of VBAS in the region."
Underlining the importance of this
milestone, Vycor has received an opening order for the Chinese
market with a value of $170,000,
which it shipped prior to the end of December 2011.
For more information about how VBAS
works, or to read testimonials, please visit
www.vycormedical.com
About Vycor Medical, Inc.
With corporate headquarters in
Boca Raton, FL, Vycor Medical,
Inc. (VYCO.BB) is a medical device company committed to making
neurological brain, spinal and other surgical procedures safer and
more effective. The company's flagship, Patent Pending
ViewSite™ Surgical Access Systems represent an exciting new
minimally invasive access and retraction system that holds the
potential for speedier, safer and more economical brain, spinal and
other surgeries and a quicker patient discharge. Vycor's
innovative medical instruments are designed to optimize
neurosurgical site access, reduce patient risk, accelerate
recovery, and add tangible value to the professional medical
community. Vycor is ISO 13485:2003 compliant, has FDA 510(K)
clearance for brain and spine surgeries, and CE Marking and HPB
licensing in Canada.
Vycor Medical's subsidiary
NovaVision, Inc. researches, develops and provides science-driven
light-based neurostimulation therapy and other medical technologies
that help restore sight to patients with neurological vision
impairments. The company's proprietary, Visual Restoration
Therapy (VRT) platform is clinically supported to improve lost
vision resulting from stroke, brain cancer, traumatic brain injury
("TBI"), or other acquired brain injury, and has been cleared to be
marketed in the US by the FDA. VRT can be prescribed by any
ophthalmologist, optometrist, neurologist or physiatrist.
NovaVision also provides a device that aids in the early
identification of visual field deficits: the Head Mounted Perimeter
(HMPTM) - a portable and ADA-compliant instrument to aid in the
detection and measurement of visual field deficits even in
bed-ridden patients.
For the latest information on the
company, including media and other coverage, and to learn more,
please go online at www.vycormedical.com or www.novavision.com.
Safe Harbor
Statement
Information in this document
constitute forward-looking statements or statements which may be
deemed or construed to be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words "forecast", "anticipate", "estimate", "project",
"intend", "expect", "should", "believe", and similar expressions
are intended to identify forward-looking statements. These
forward-looking statements involve, and are subject to known and
unknown risks, uncertainties and other factors which could cause
Vycor Medical's actual results, performance (financial or
operating) or achievements to differ from the future results,
performance (financial or operating) or achievements expressed or
implied by such forward-looking statements. The risks,
uncertainties and other factors are more fully discussed in Vycor
Medical's filings with the U.S. Securities and Exchange Commission.
All forward-looking statements attributable to Vycor Medical herein
are expressly qualified in their entirety by the above-mentioned
cautionary statement. Vycor Medical disclaims any obligation to
update forward-looking statements contained in this estimate,
except as may be required by law.
Contact:
Karen Coviello, 561-558-2000,
kacoviello@novavision.com
SOURCE Vycor Medical